Imetrx Inc.

An interview with a pioneer in European interventional cardiology, who's had a role in changing the mindset of European physicians to bring together clinical practice and new product development. By D

interest in vulnerable plaque is erupting. Device companies have taken the lead, but as biologic solution emerge, will that lead last? The second of a two-part series. by David Cassak As we noted last

Vulnerable plaque is the hottest cardiovascular device opportunity in years. But in shifting thinking about coronary disease from structural to biological processes, it challenges what it means to be

Better understanding and detection of plaque may lead to new treatments for symptomless heart disease patients at risk. by Mary Stuart Heart disease, "the silent killer," is even more silent than we t